1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Exosome-Based Cancer Therapy CDMO Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Exosome-Based Cancer Therapy CDMO Market, by Exosome Type / Source
8.1.1. Autologous Exosomes
8.1.1.1. Market Revenue and Forecast
8.1.2. Allogeneic Exosomes
8.1.2.1. Market Revenue and Forecast
8.1.3. Engineered / Modified Exosomes
8.1.3.1. Market Revenue and Forecast
8.1.4. Others
8.1.4.1. Market Revenue and Forecast
9.1. Exosome-Based Cancer Therapy CDMO Market, by Service Type
9.1.1. Exosome Isolation & Purification
9.1.1.1. Market Revenue and Forecast
9.1.2. Upstream Processing
9.1.2.1. Market Revenue and Forecast
9.1.3. Cargo Loading & Engineering
9.1.3.1. Market Revenue and Forecast
9.1.4. Downstream Purification
9.1.4.1. Market Revenue and Forecast
9.1.5. Formulation Development
9.1.5.1. Market Revenue and Forecast
9.1.6. Analytical & Characterization Services
9.1.6.1. Market Revenue and Forecast
9.1.7. Fill-Finish & Packaging
9.1.7.1. Market Revenue and Forecast
9.1.8. Others
9.1.8.1. Market Revenue and Forecast
10.1. Exosome-Based Cancer Therapy CDMO Market, by Therapeutic Application
10.1.1. Solid Tumors
10.1.1.1. Market Revenue and Forecast
10.1.2. Hematologic Cancers
10.1.2.1. Market Revenue and Forecast
10.1.3. Others
10.1.3.1. Market Revenue and Forecast
11.1. Exosome-Based Cancer Therapy CDMO Market, by End User
11.1.1. Biopharmaceutical Companies
11.1.1.1. Market Revenue and Forecast
11.1.2. Biotechnology Startups
11.1.2.1. Market Revenue and Forecast
11.1.3. Research Institutes
11.1.3.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Exosome Type / Source
12.1.2. Market Revenue and Forecast, by Service Type
12.1.3. Market Revenue and Forecast, by Therapeutic Application
12.1.4. Market Revenue and Forecast, by End User
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Exosome Type / Source
12.1.5.2. Market Revenue and Forecast, by Service Type
12.1.5.3. Market Revenue and Forecast, by Therapeutic Application
12.1.5.4. Market Revenue and Forecast, by End User
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Exosome Type / Source
12.1.6.2. Market Revenue and Forecast, by Service Type
12.1.6.3. Market Revenue and Forecast, by Therapeutic Application
12.1.6.4. Market Revenue and Forecast, by End User
12.2. Europe
12.2.1. Market Revenue and Forecast, by Exosome Type / Source
12.2.2. Market Revenue and Forecast, by Service Type
12.2.3. Market Revenue and Forecast, by Therapeutic Application
12.2.4. Market Revenue and Forecast, by End User
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Exosome Type / Source
12.2.5.2. Market Revenue and Forecast, by Service Type
12.2.5.3. Market Revenue and Forecast, by Therapeutic Application
12.2.5.4. Market Revenue and Forecast, by End User
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Exosome Type / Source
12.2.6.2. Market Revenue and Forecast, by Service Type
12.2.6.3. Market Revenue and Forecast, by Therapeutic Application
12.2.6.4. Market Revenue and Forecast, by End User
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Exosome Type / Source
12.2.7.2. Market Revenue and Forecast, by Service Type
12.2.7.3. Market Revenue and Forecast, by Therapeutic Application
12.2.7.4. Market Revenue and Forecast, by End User
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Exosome Type / Source
12.2.8.2. Market Revenue and Forecast, by Service Type
12.2.8.3. Market Revenue and Forecast, by Therapeutic Application
12.2.8.4. Market Revenue and Forecast, by End User
12.3. APAC
12.3.1. Market Revenue and Forecast, by Exosome Type / Source
12.3.2. Market Revenue and Forecast, by Service Type
12.3.3. Market Revenue and Forecast, by Therapeutic Application
12.3.4. Market Revenue and Forecast, by End User
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Exosome Type / Source
12.3.5.2. Market Revenue and Forecast, by Service Type
12.3.5.3. Market Revenue and Forecast, by Therapeutic Application
12.3.5.4. Market Revenue and Forecast, by End User
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Exosome Type / Source
12.3.6.2. Market Revenue and Forecast, by Service Type
12.3.6.3. Market Revenue and Forecast, by Therapeutic Application
12.3.6.4. Market Revenue and Forecast, by End User
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Exosome Type / Source
12.3.7.2. Market Revenue and Forecast, by Service Type
12.3.7.3. Market Revenue and Forecast, by Therapeutic Application
12.3.7.4. Market Revenue and Forecast, by End User
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Exosome Type / Source
12.3.8.2. Market Revenue and Forecast, by Service Type
12.3.8.3. Market Revenue and Forecast, by Therapeutic Application
12.3.8.4. Market Revenue and Forecast, by End User
12.4. MEA
12.4.1. Market Revenue and Forecast, by Exosome Type / Source
12.4.2. Market Revenue and Forecast, by Service Type
12.4.3. Market Revenue and Forecast, by Therapeutic Application
12.4.4. Market Revenue and Forecast, by End User
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Exosome Type / Source
12.4.5.2. Market Revenue and Forecast, by Service Type
12.4.5.3. Market Revenue and Forecast, by Therapeutic Application
12.4.5.4. Market Revenue and Forecast, by End User
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Exosome Type / Source
12.4.6.2. Market Revenue and Forecast, by Service Type
12.4.6.3. Market Revenue and Forecast, by Therapeutic Application
12.4.6.4. Market Revenue and Forecast, by End User
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Exosome Type / Source
12.4.7.2. Market Revenue and Forecast, by Service Type
12.4.7.3. Market Revenue and Forecast, by Therapeutic Application
12.4.7.4. Market Revenue and Forecast, by End User
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Exosome Type / Source
12.4.8.2. Market Revenue and Forecast, by Service Type
12.4.8.3. Market Revenue and Forecast, by Therapeutic Application
12.4.8.4. Market Revenue and Forecast, by End User
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Exosome Type / Source
12.5.2. Market Revenue and Forecast, by Service Type
12.5.3. Market Revenue and Forecast, by Therapeutic Application
12.5.4. Market Revenue and Forecast, by End User
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Exosome Type / Source
12.5.5.2. Market Revenue and Forecast, by Service Type
12.5.5.3. Market Revenue and Forecast, by Therapeutic Application
12.5.5.4. Market Revenue and Forecast, by End User
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Exosome Type / Source
12.5.6.2. Market Revenue and Forecast, by Service Type
12.5.6.3. Market Revenue and Forecast, by Therapeutic Application
12.5.6.4. Market Revenue and Forecast, by End User
13.1. Lonza Group
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. WuXi AppTec
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Catalent
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Fujifilm Diosynth Biotechnologies
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Samsung Biologics
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Curia
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Codiak BioSciences
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Evox Therapeutics
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Thermo Fisher Scientific / Patheon Biologics
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. KBI Biopharma
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
